Sanofi Exit From Sickle Cell Gene Therapy Leaves Sangamo With Difficult Decision
Adds To Hemophilia A Problems
Sanofi’s decision is influenced by its own in-house options, but also by the growing competition in sickle cell gene therapy.
You may also be interested in...
Share prices for many gene-editing companies declined in 2021, but the field is burgeoning with novel approaches due to be highlighted at the J.P. Morgan meeting, and one player, Intellia, could move closer to a breakthrough in 2022.
New data show fitusiran’s promise across hemophilia A and B, but a switch to a lower dose prompted by safety concerns will delay its filing until 2024.
Arthur Lahr, CEO of the Dutch biotech, said the offer is testimony to the uniqueness of the firm's natural killer (NK) cell platform "and the rapid success of Kiadis’s transformation."